NEVVI Medicare utilization intelligence

← back

RUBIN, NANCYD.O. NPI 1003980947 Clinician

Medical Oncology · MONTEREY, CA

Specialty Medical Oncology — from billed Medicare claims
In practice about 29 years since medical school (class of 1997, self-reported to CMS)
Location MONTEREY, CA · NPPES registered location
Active in data Billed Medicare 2020–2024 (5 consecutive years)
Scale 65 codes billed · 314,048 disclosed services (CY2024 — most recent year in data)
Current groups

Group affiliation since 2019

20192026
MONTEREY BAY ONCOLOGY A MEDICAL CORPORATION
2019–2026

The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.

NPPES registry · CMS Doctors & Clinicians registry · Medicare Part B physician/supplier claims · NPPES record last updated 2014-01

Year: 2024 · 2023 · 2022  · 2021  · 2020 

Provider overview · all codes · CY2024

The full analytics for this provider

Premium

The billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.

This provider's disclosed Medicare payments across all codes were in CY2024. Unlock to see the figure.

  • Payment, service & beneficiary totals — the disclosed scale, all codes
  • Practice profile — focus & reach — top codes by share of services
  • Office vs. facility setting mix — place-of-service code split
  • Volume over five years — discrete yearly counts, no rate
  • Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
  • Peer positioning — code breadth — how many codes billed, vs peers

Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.

Notify me at launch → Or see a live example profile →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
J1439 Injection, ferric carboxymaltose, 1 mg
J1442 Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram
J0897 Injection, denosumab, 1 mg
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
J9271 Injection, pembrolizumab, 1 mg
J9267 Injection, paclitaxel, 1 mg
J9263 Injection, oxaliplatin, 0.5 mg
J1453 Injection, fosaprepitant, 1 mg
J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J2357 Injection, omalizumab, 5 mg
J1449 Injection, eflapegrastim-xnst, 0.1 mg
J9395 Injection, fulvestrant, 25 mg
J9304 Injection, pemetrexed (pemfexy), 10 mg
J9171 Injection, docetaxel, 1 mg
Q5107 Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg
36415 Insertion of needle into vein for collection of blood sample
Q5123 Injection, rituximab-arrx, biosimilar, (riabni), 10 mg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
Q5126 Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg
J2469 Injection, palonosetron hcl, 25 mcg
J1745 Injection, infliximab, excludes biosimilar, 10 mg
96372 Injection of drug or substance under skin or into muscle
J9201 Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
96413 Administration of chemotherapy into vein, 1 hour or less
J9045 Injection, carboplatin, 50 mg
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
J9190 Injection, fluorouracil, 500 mg
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
J1200 Injection, diphenhydramine hcl, up to 50 mg
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
96417 Administration of additional new drug or substance into vein, 1 hour or less
J3490 Unclassified drugs
96415 Administration of chemotherapy into vein, each additional hour
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
J3489 Injection, zoledronic acid, 1 mg
96375 Injection of additional new drug or substance into vein
99491 Chronic care management services for two or more chronic conditions, first 30 minutes provided personally by health care professional, per calendar month
99211 Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
96361 Infusion into a vein for hydration, each additional hour
96411 Administration of additional new drug or substance into vein using push technique
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
J7030 Infusion, normal saline solution , 1000 cc
96523 Irrigation of implanted venous access drug delivery device
J1454 Injection, fosnetupitant 235 mg and palonosetron 0.25 mg
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
81002 Urinalysis, manual test
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
G2012 Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic
99443 Telephone medical discussion with physician, 21-30 minutes
96416 Administration of prolonged chemotherapy into vein
51720 Instillation of anti-cancer drug into bladder
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
99442 Telephone medical discussion with physician, 11-20 minutes
J1720 Injection, hydrocortisone sodium succinate, up to 100 mg

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.